Topics

Cambridge Company Raises €20M for Potential First in Lung Disease

08:45 EST 20 Dec 2018 | Labiotech.eu

Morphogen-IX, based in Cambridge, has raised €20.4M (£18.4M) to fund a new type of treatments for pulmonary arterial hypertension. The Series B financing will go towards the preclinical development of the company’s lead candidate, which has the potential to become ...

The post Cambridge Company Raises €20M for Potential First in Lung Disease appeared first on Labiotech.eu.

Original Article: Cambridge Company Raises €20M for Potential First in Lung Disease

NEXT ARTICLE

More From BioPortfolio on "Cambridge Company Raises €20M for Potential First in Lung Disease"

Quick Search